Trimethoprim/Sulfonamide

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

The whole-only 120 mg tablet corresponds to an 8 kg step at 15 mg/kg. Crushing permits compounding but not accurate casual division, so many dogs need a validated liquid preparation.

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

A typical 4 kg cat needs about 60 mg, half of this whole-only tablet. Accurate use therefore requires validated compounding rather than informal splitting.

The exact human suspension has a current Polish/EU SPC, but its Georgian certificate expired in May 2026 and veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

The 48 mg/ml suspension permits weight-based measurement (about 0.3125 ml/kg at 15 mg/kg) and is the most workable presentation; shaking, calibrated oral measurement and palatability still matter.

The exact human suspension has a current Polish/EU SPC, but its Georgian certificate expired in May 2026 and veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

The 48 mg/ml suspension permits weight-based measurement (about 0.3125 ml/kg at 15 mg/kg) and is the most workable presentation; shaking, calibrated oral measurement and palatability still matter.

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

Current UTI and pyoderma guidance supports potentiated sulfonamides for selected susceptible infections; an 84-dog UTI study and modern eight-dog TMP-SMX PK study add direct support. Evidence is uneven across the broad antimicrobial and antiprotozoal scope, so culture and diagnosis remain decisive.

A 2026 systematic review estimated mild adverse events at 2.3% and severe events at 0.2% in dogs, but KCS, immune polyarthritis, hepatopathy and blood dyscrasias can be serious and are more often reported after courses longer than seven days.

The scored 480 mg tablet permits only 240 mg steps, equivalent to 16 kg at the common 15 mg/kg dose; smaller or intermediate dogs need a validated compounded alternative.

The exact human tablet is currently registered in Georgia and the EU with a public Polish SPC, but veterinary use is off-label. Veterinary labels and current guidelines support the active combination, not this exact product.

UTI and feline lower-urinary-tract guidance recognises trimethoprim-sulfonamide as a first-line option when antimicrobial treatment is truly indicated, but direct feline clinical and PK evidence for oral TMP-SMX is limited and Enterococcus is intrinsically resistant.

Comparative evidence does not show a large overall excess of adverse events, but feline safety data are much thinner than canine data. Gastrointestinal effects, hypersensitivity, crystalluria and haematologic or hepatic injury require selection, hydration and monitoring.

A typical 4 kg cat needs about 60 mg at 15 mg/kg, one eighth of this tablet; the tablet is validated only for halves, so accurate direct dosing is not feasible.

Exact identity, strength, current manufacturer instruction and Georgian registration are verifiable, and internationally authorised same-class or same-formulation controls exist. However, the exact product lacks an accessible internationally recognised regulator SPC and independent exact-product outcome data.

Potentiated sulfonamides have guideline-supported roles in selected susceptible canine infections and direct canine cystitis trial evidence. Benefit remains culture- and syndrome-dependent; the broad label and mainly oral evidence do not prove equal efficacy of this injection across every listed infection.

A 3–5-day course limits cumulative toxicity, but dogs are unusually susceptible to KCS, hepatopathy, skin eruptions, blood dyscrasias, polyarthropathy and other idiosyncratic sulfonamide reactions. Hydration, organ and hypersensitivity boundaries are clinically material; slow IV use adds acute intolerance risk.

Once-daily dosing for 3–5 days is workable in a clinic and IM administration is straightforward; slow IV requires venous access, monitoring and emergency readiness. The 50 ml companion-animal vial is much larger than many individual courses and can create wastage.

Exact identity, strength, current manufacturer instruction and Georgian registration are verifiable, and internationally authorised same-class or same-formulation controls exist. However, the exact product lacks an accessible internationally recognised regulator SPC and independent exact-product outcome data.

The active class has a recognised role in selected susceptible feline infections and valid dog/cat injectable analogues exist, but direct feline clinical outcomes for this exact product and route were not identified. The broad label therefore rests mainly on class evidence and susceptibility.

The labelled course is short and IM-only use avoids IV intolerance, but hypersensitivity, crystalluria/renal injury, folate-haematopoietic toxicity, liver disease and local reaction remain meaningful. Exact feline reproductive and outcome safety data are sparse.

Once-daily IM treatment for 3–5 days is feasible in clinic, but repeated feline restraint and injection are material burdens. The small 0.125 ml/kg volume requires an accurately graduated syringe, while the required 50 ml vial creates substantial single-patient wastage.